Skip to main content
. 2018 Apr 4;2018(4):CD006349. doi: 10.1002/14651858.CD006349.pub3
Trial name or title The effectiveness and safety of vertebroplasty for osteoporotic vertebral compression fractures. A double blind, prospective, randomised, controlled study
Methods Randomised controlled trial, participant blinded
Participants Planned sample size = 164
Inclusion criteria
  • More than or equal to 50 years of age

  • Back pain (more than or equal to 4 on 0 to 10 scale)

  • 1 to 3 recent painful osteoporotic vertebral fractures (minimum 15% loss of height, oedema or fracture line within vertebral body) from T5 through L5

  • Decreased bone density T‐score less than or equal to ‐1.


Exclusion criteria
  • More than 3 recent spine fractures, pedicle fracture, or previous vertebroplasty or kyphoplasty and neurological deficit, radicular pain, radicular and/or myelum compression syndrome or canal narrowing

  • More than 90% osteoporotic vertebral collapse, fracture through/destruction of posterior wall, retropulsed bony fragment or bone fragments impinging on spinal cord

  • Spinal or systemic infections

  • Vertebral fractures resulting from primary bone tumours osteoblastic metastases or current malignancy

  • Severe cardio‐pulmonary condition

  • Dementia

  • Untreatable coagulopathy or uninterruptible anticoagulation therapy

  • Allergies to materials used in vertebroplasty or kyphoplasty materials and contraindications to MRI

  • Unable to give informed consent

Interventions
  • Vertebroplasty

  • Three weeks period of bed rest, wearing a rigid hyperextension suspension brace, with positive three‐point suspension (sternal, suprapubic and thoracolumbar)

Outcomes Duration of follow‐up to 24 months
Primary outcome
  1. VAS score (10 cm scale ‐ 0 (no pain) to 10 (worst pain ever)


Secondary outcomes
  • RMDQ

  • ODI (version 2.0)

  • Assessment of Quality of life (AQoL)

  • Utility score (Health‐related questionnaire)

  • Incidence of new fractures (plain film examination of the thoracic and lumbosacral spine at 1, 3, 6, 12 and 24 months)

Starting date Not specified
Contact information Principal Investigator: Umile Giuseppe Longo, MD, Italy Phone: +39 06 22 54 11 E‐mail: g.longo@unicampus.it
Notes Unclear if registered in a trial registry
Primary sponsor: Not specified
Status of trial unknown